*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1991 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus and should not be redistributed.  Any       *x*
*x*    research using this corpus or based on it should acknowledge     *x*
*x*    that fact, as well as the preliminary nature of the corpus.      *x*
*x*                             (9/9/1991)                             *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*


(  END_OF_TEXT_UNIT)
( (S  (ADVP Interestingly
	    enough)
      ,
      (S (S (NP the effect
		(PP of
		    (NP the digitalis glycosides)))
	    (X (X (AUX is)
		  (VP inhibited
	     
		      (PP by
			  (NP a high concentration
			      (PP of
				  (NP potassium))
			      (PP in
				  (NP the incubation medium))))))
	       and
	       (X  
		(AUX is)
		(VP enhanced
	      
		    (PP by
			(NP the absence
			    (PP of
				(NP potassium))))))))
	 *LRB*
	 (NP (NP Wolff)
	     ,
	     (NP 1960))
	 *RRB*))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((NP (NP B.)
     (NP Organification
	 (PP of
	     (NP iodine)))))
( (S
   (NP The precise mechanism
       (PP for
	   (NP organification
	       (PP of
		   (NP iodine))
	       (PP in
		   (NP the thyroid)))))
   (AUX is)
   (NEG not)
   (ADVP as
	 yet)
   (VP  (ADVP completely)
	understood
	))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP However)
      ,
      (S  
       (NP the formation
	   (PP of
	       (NP (NP (VP    organically
			      bound)
		       iodine)
		   ,
		   (NP   mainly
			 mono-iodotyrosine)
		   ,)))
       (AUX can)
       (VP be
	   (VP accomplished
	      
	       (PP in
		   (NP (ADJP cell-free) systems))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP the absence
	   (PP of
	       (NP additions
		   (PP to
		       (NP the homogenate))))))
   ,
   (S (S (NP (NP the product)
	     (VP formed))
	 (VP is
	     (NP an
		 iodinated particulate
		 protein)))
      *LRB*
      (NP (NP (NP Fawcett)
	      and
	      (NP Kirkwood))
	  ,
	  (NP 1953)
	  ;
	  ;
	  (NP (NP (NP Taurog)
		  ,
		  (NP Potter)
		  and
		  (NP Chaikoff))
	      ,
	      (NP 1955))
	  ;
	  ;
	  (NP (NP (NP Taurog)
		  ,
		  (NP Potter)
		  ,
		  (NP Tong)
		  ,
		  and
		  (NP Chaikoff))
	      ,
	      (NP 1956))
	  ;
	  ;
	  (NP (NP (NP Serif)
		  and
		  (NP Kirkwood))
	      ,
	      (NP 1958))
	  ;
	  ;
	  (NP (NP (NP De Groot)
		  and
		  (NP Carvalho))
	      ,
	      (NP 1960)))
      *RRB*))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP This iodoprotein)
      (AUX does)
      (NEG not)
      (VP appear
	  (S (NP *)
	     (AUX to)
	     (VP be
		 (NP the
		     (ADJP same)
		     (PP as
			 (SBAR (WHNP what)
			       (S  (NP T)  
				   (VP is
				       (ADVP normally)
				       (ADJP present
					     (PP in
						 (NP the thyroid))))))))))))
     ,
     and
     (S (NP there)
	(VP is
	    (NP no evidence
		(ADVP so
		      far)
		(SBAR that
		      (S (NP  thyroglobulin)
			 (AUX can)
			 (VP be
			     (VP iodinated
				  
				 (PP in
				     (NP vitro))
				 (PP by
				     (NP (ADJP cell-free) systems))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (PP In
      (NP addition))
  ,
  (S (NP (NP the iodoamino acid)
	 (VP formed
	     (PP in
		 (NP 
		  largest
		  quantity))
	     (PP in
		 (NP the intact thyroid))))
     (VP is
	 (NP di-iodotyrosine))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S  
      (SBAR  If
	     (S (NP (NP tyrosine)
		    and
		    (NP a (ADJP system
				generating)
			hydrogen peroxide))
		(AUX are)
		(VP added
		  
		    (PP to
			(NP a (ADJP cell-free) homogenate
			    (PP of
				(NP the thyroid)))))))
      ,
      (S (NP large quantities
	     (PP of
		 (NP free mono-iodotyrosine)))
	 (AUX can)
	 (VP be
	     (VP formed
		 ))))
     *LRB*
     (NP (NP Alexander)
	 ,
	 (NP 1959))
     *RRB*)
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP It
	  (SBAR-1 *pseudo-attach*))
      (VP is
	  (NEG not)
	  (ADJP clear))
      (SBAR-1 whether
	      (S (NP this system)
		 (VP bears
		     (NP any resemblance
			 (PP to
			     (NP the
				 in
				 vivo
				 iodinating
				 mechanism)))))))
     ,
     and
     (S (NP a (ADJP system
		    generating)
	    peroxide)
	(AUX has)
	(NEG not)
	(VP been
	    (VP identified
	      
		(PP in
		    (NP thyroid tissue))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (PP On
	 (NP chemical grounds))
     (S
      (NP it
	  (SBAR-2 *pseudo-attach*))
      (VP seems
	  (ADJP  most likely))
      (SBAR-2 that
	      (S (NP iodide)
		 (AUX is)
		 (VP (ADVP first)
		     (VP converted
			 (PP to
			     (NP A[fj])))
		     and
		     (ADVP then)
		     (X  
		      (PP to
			  (NP A[fj])))
		     (PP as
			 (NP the
			     active
			     (VP iodinating)
			     species)))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (PP In
	 (NP the thyroid gland))
     (S (NP it)
	(VP appears
	    (SBAR (SBAR that
			(S (NP (NP proteins)
			       *LRB*
			       (NP  (ADVP chiefly)
				    thyroglobulin)
			       *RRB*)
			   (AUX are)
			   (VP iodinated
			       )))
		  and
		  (SBAR that
			(S (NP free tyrosine and thyronine)
			   (AUX are)
			   (NEG not)
			   (VP iodinated
			       )))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP Iodination
      (PP of
	  (NP tyrosine)))
  ,
  (ADVP however)
  ,
  (VP is
      (NEG not)
      (ADJP enough
	    (PP for
		(NP the synthesis
		    (PP of
			(NP hormone)))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP The mono
      -
      and
      di-iodotyrosine)
  (AUX must)
  (VP be
      (VP coupled
	  ))
  (S   (NP *) 
       (AUX to)
       (VP form
	   (NP  (NP tri-iodothyronine) and (NP thyroxine)))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (S (NP The mechanism
	  (PP of
	      (NP this coupling)))
      (X (X (AUX has)
	    (VP been
		(VP studied
		     
		    (PP in
			(NP some detail))))
	    (PP with
		(NP (ADJP non-enzymatic) systems
		    (PP in
			(NP vitro)))))
	 and
	 (X  
	  (AUX can)
	  (VP be
	      (VP simulated
	       
		  (PP by
		      (NP certain di-iodotyrosine analogues)))))))
   *LRB*
   (NP (NP (NP Pitt-Rivers)
	   and
	   (NP James))
       ,
       (NP 1958))
   *RRB*)
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP There)
   (VP is
       (ADVP so
	     far)
       (NP no evidence
	   (S (NP *)
	      (AUX to)
	      (VP indicate
		  (ADVP conclusively)
		  (SBAR that
			(S (NP this coupling)
			   (VP is
			       (PP under
				   (NP enzymatic control))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  
 (S (NP The chemical nature
	(PP of
	    (NP the iodocompounds)))
    (AUX is)
    (VP discussed
		 
	(ADVP (ADVP below)
	      *LRB*
	      (NP pp. 76
		  et
		  seq
		  .)
	      *RRB*)))
 .)
(  END_OF_TEXT_UNIT) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  (NP (NP C
	   .)
       (NP Thyroglobulin synthesis)))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Little)
   (AUX is)
   (VP known
       (PP of
	   (NP the synthetic mechanisms
	       (PP for
		   (NP formation
		       (PP of
			   (NP thyroglobulin))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (S (NP Its synthesis)
      (AUX has)
      (NEG not)
      (VP been
	  (VP demonstrated
		     
	      (PP in
		  (NP (ADJP cell-free) systems)))))
   ,
   nor
   (SINV  
    (AUX has)
    (NP its synthesis
	(PP by
	    (NP systems
		(PP with
		    (NP intact thyroid cells
			(PP in
			    (NP vitro)))))))
    (VP been
	(VP  (ADVP unequivocally)
	     proven))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  (S (S
       (NP There)
       (VP is
	   (NP some reason
	       (S (NP *)
		  (AUX to)
		  (VP think
		      (SBAR that
			    (S (NP thyroglobulin synthesis)
			       (AUX may)
			       (VP proceed
				   (ADVP independently
					 (PP of
					     (NP iodination)))))))))))
      ,
      for
      (S (S  
	  (PP in
	      (NP (NP 
		   certain transplantable
		   tumours
		   (PP of
		       (NP the rat thyroid)))
		  (VP containing
		      (NP  (ADVP essentially)
			   no (VP iodinated) thyroglobulin))))
	  ,
	  (S (NP (NP a protein)
		 (SBAR (WHNP that)
		       (S  (NP T) 
			   (VP appears
			       (S (NP *)
				  (AUX to)
				  (VP be
				      (NP thyroglobulin)))))))
	     (AUX has)
	     (VP been
		 (VP observed
	       
		     (PP in
			 (NP ultracentrifuge experiments))))))
	 *LRB*
	 (NP (NP (NP Wolff)
		 ,
		 (NP Robbins)
		 and
		 (NP Rall))
	     ,
	     (NP 1959))
	 *RRB*))
   .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Similar findings)
   (AUX have)
   (VP been
       (VP noted
		 
	   (PP in
	       (NP (NP a patient
		       (PP with
			   (NP congenital absence
			       (PP of
				   (NP the organification enzymes)))))
		   ,
		   (SBAR 
		    (WHNP whose thyroid tissue)
		    (S (NP T)
		       (AUX could)
		       (VP (ADVP only)
			   concentrate
			   (NP iodide)))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP addition))
   ,
   (S  
    (VP depending
	(PP on
	    (NP availability
		(PP of
		    (NP dietary iodine)))))
    ,
    (S (NP thyroglobulin)
       (AUX may)
       (VP contain
	   (NP  (ADJP varying)
		quantities
		(PP of
		    (NP iodine)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  (NP (NP D .)
       (NP Secretion)))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S  
  (SBAR  Since
	 (S (NP the circulating thyroid hormones)
	    (VP are
		(NP the amino acids
		    thyroxine and tri-iodothyronine))
	    *LRB*
	    (NP cf. Section
		C)
	    *RRB*))
  ,
  (S (NP it
	 (SBAR-3 *pseudo-attach*))
     (VP is
	 (ADJP clear))
     (SBAR-3 that
	     (S (NP some mechanism
		    (PP-4 *pseudo-attach*))
		(AUX must)
		(VP exist
		    (PP in
			(NP the thyroid gland)))
		(PP-4 for
		      (NP their release
			  (PP from
			      (NP proteins))
			  (PP before
			      (NP secretion))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The presence
       (PP of
	   (NP several proteases and peptidases)))
   (AUX has)
   (VP been
       (VP demonstrated
		 
	   (PP in
	       (NP the thyroid)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (S (NP One
	      (PP of
		  (NP the proteases)))
	  (VP has
	      (NP pH optimum
		  (PP of
		      (NP (ADVP about)
			  3.7)))))
       and
       (X  (NP another)
	   (PP of
	       (NP (ADVP about)
		   5.7))))
    *LRB*
    (NP (NP (NP (NP McQuillan)
		,
		(NP Stanley)
		and
		(NP Trikojus))
	    ,
	    (NP 1954))
	;
	;
	(NP (NP (NP Alpers)
		,
		(NP Robbins)
		and
		(NP Rall))
	    ,
	    (NP 1955)))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The finding
       (SBAR that
	     (S (NP the concentration
		    (PP of
			(NP one
			    (PP of
				(NP these proteases)))))
		(AUX is)
		(VP increased
		    )
		(PP in
		    (NP thyroid glands
			(PP from
			    (NP (ADJP TSH-treated) animals)))))))
   (VP suggests
       (SBAR that
	     (S (NP this protease)
		(AUX may)
		(VP be
		    (ADJP active)
		    (PP in
			(NP vivo)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP There)
      (VP is
	  (NP no conclusive evidence
	      (ADVP yet)
	      (SBAR that
		    (S (NP either
			   (PP of
			       (NP the proteases)))
		       (AUX has)
		       (VP been
			   (VP prepared
				     
			       (PP in
	    
				   (NP (ADJP   highly
						  purified)
				       form)))))))))
     nor
     (SINV  
      (AUX is)
      (NP their specificity)
      (VP known)))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (NP A study
	   (PP of
	       (NP their activity
		   (PP on
		       (NP thyroglobulin)))))
       (AUX has)
       (VP shown
	   (SBAR (SBAR that
		       (S (NP  thyroxine)
			  (AUX is)
			  (NEG not)
			  (VP  (ADVP preferentially)
			       released
			       )))
		 and
		 (SBAR that
		       (S (NP the degradation)
			  (VP proceeds
			      (ADVP stepwise)
			      (PP with
				  (NP the formation
				      (PP of
					  (NP macromolecular intermediates))))))))))
    *LRB*
    (NP (NP (NP Alpers)
	    ,
	    (NP Petermann)
	    and
	    (NP Rall))
	,
	(NP 1956))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (PP Besides
	 (NP proteolytic enzymes))
     (S (NP the thyroid)
	(VP possesses
	    (NP  (VP de-iodinating)
		 enzymes))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( 
 (S (S  
     (NP (NP A microsomal de-iodinase)
	 (X (PP with
		(NP a pH optimum
		    (PP of
			(NP (ADVP around)
			    8))))
	    ,
	    and
	    (VP requiring
		(NP (VP reduced)
		    triphosphopyridine nucleotide)
		(PP for
		    (NP activity)))
	    ,))
     (AUX has)
     (VP been
	 (VP identified
	   
	     (PP in
		 (NP the thyroid)))))
    *LRB*
    (NP (NP Stanbury)
	,
	(NP 1957))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
( (S
   (NP This (VP de-iodinating) enzyme)
   (X (VP is
	  (ADJP effective
		(PP against
		    (NP  mono
			 -
			 and
			 di-iodotyrosine))))
      ,
      but
      (X  
       (AUX does)
       (NEG not)
       (VP de-iodinate
	   (NP (NP thyroxine) or (NP tri-iodothyronine))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP It)
   (AUX is)
   (VP assumed
       (SBAR that
	     (S (NP (NP the iodine)
		    (VP released
			(PP from
			    (NP the iodotyrosines))))
		(VP remains
		    
		    (PP in
			(NP (NP the iodide pool
				(PP of
				    (NP the thyroid)))
			    ,
			    (SBAR 
			     (WHADVP where)
			     (S (NP it)
				(AUX is)
				(VP (NP oxidised)
				    and
				    (VP re-incorporated
					(PP into
					    (NP thyroglobulin)))))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S (NP (NP The thyroxine and tri-iodothyronine)
	(VP (VP released
		(PP by
		    (NP proteolysis)))
	    and
	    (VP  (ADVP so)
		 escaping
		 (NP de-iodination))))
    (ADVP presumably)
    (VP diffuse
	(PP into
	    (NP the blood stream))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP It
	  (SBAR-5 *pseudo-attach*))
      (AUX has)
      (VP been
	  (VP shown))
      (SBAR-5 that
	      (S (NP thyroglobulin)
		 (VP binds
		     (NP thyroxine)))))
     ,
     but
     (S (NP the binding)
	(AUX does)
	(NEG not)
	(VP appear
	     
	    (S (NP *)
	       (AUX to)
	       (VP be  
		   (ADJP (ADVP particularly)
			 strong))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (NP It
	   (SBAR-6 *pseudo-attach*))
       (AUX has)
       (VP been
	   (VP suggested))
       (SBAR-6 that
	       (S (NP (NP the plasma (ADJP thyroxine-binding) proteins)
		      ,
		      (SBAR 
		       (WHNP which)
		       (S (NP T)
			  (VP have
			      (NP an
				  (ADJP  extremely
					 high) affinity
				  (PP for
				      (NP thyroxine))))))
		      ,)
		  (VP compete
		  
		      (PP with
			  (NP thyroglobulin))
		      (PP for
			  (NP thyroxine))))))
    *LRB*
    (NP (NP (NP Ingbar)
	    and
	    (NP Freinkel))
	,
	(NP 1957))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  (NP (NP E .)
       (NP Antithyroid drugs)))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(
 (S (NP Antithyroid drugs)
    (VP are
	(PP of
	    (NP two general types))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP One type)
   (VP has
       (NP a
	   small univalent
	   anion
	   (PP of
	       (NP the (ADJP thiocyanate-perchlorate-fluoro) type)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP This ion)
   (VP inhibits
       (NP thyroid hormone synthesis)
       (PP by
	   (S (NP *) 
	      (VP interfering
		  (PP with
		      (NP iodide concentration
			  (PP in
			      (NP the thyroid)))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP It)
   (AUX does)
   (NEG not)
   (VP appear
       (S (NP *)
	  (AUX to)
	  (VP affect
	      (NP the (VP iodinating) mechanism)
	      (PP as
		  (ADJP such))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The other group
       (PP of
	   (NP antithyroid agents or drugs)))
   (AUX is)
   (VP typified
	     
       (PP by
	   (NP thiouracil))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP These drugs)
      (VP have
	  (NP no effect
	      (PP on
		  (NP the (ADJP iodide
				concentrating)
		      mechanism)))))
     ,
     but
     (S (NP they)
	(VP inhibit
	    (NP organification))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (S (NP The mechanism
	      (PP of
		  (NP action))
	      (PP of
		  (NP these drugs)))
	  (AUX has)
	  (NEG not)
	  (VP been
	      (VP  (ADVP completely)
		   worked
		   (PRT out))))
       ,
       but
       (S  
	(NP certain
	    (PP of
		(NP them)))
	(VP appear
	    (S (NP *)
	       (AUX to)
	       (VP act
		   (PP by
		       (S (NP *) 
			  (VP reducing
			      (NP the   (VP oxidised) form
				  (PP of
				      (NP iodine))))
			  (PP before
			      (S (NP it)
				 (AUX can)
				 (VP iodinate
				     (NP thyroglobulin)))))))))))
    *LRB*
    (NP (NP Astwood)
	,
	(NP 1954))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP On
       (NP the other hand))
   ,
   (S (NP there)
      (VP are
	  (NP (NP (NP a few antithyroid drugs
		      (PP of
			  (NP this
			      same general
			      type)))
		  ,
		  (ADJP such
			(PP as
			    (NP resorcinol)))
		  ,)
	      (VP  (VP possessing
		       (NP no reducing activity))
		   and
		   (VP (ADVP possibly)
		       acting
		       (PP through
			   (NP formation
			       (PP of
				   (NP a complex))
			       (PP with
				   (NP molecular iodine))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP Any
      (PP of
	  (NP the antithyroid drugs
	      ,
	      (PP of
		  (NP either type))
	      ,)))
  (SBAR if
	(S  (NP *)  
	    (VP given
		(PP in
		    (NP 
		     (ADJP large enough)
		     doses))
		(PP for
		    (NP a long period
			(PP of
			    (NP time)))))))
  (AUX will)
  (VP cause
      (NP goitre))
  ,
  (VP  owing
       (PP to
	   (NP inhibition
	       (PP of
		   (NP thyroid hormone synthesis))
	       ,
	       (PP with
		   (NP production
		       (PP of
			   (NP hypothyroidism))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The anterior lobe
       (PP of
	   (NP the pituitary)))
   (ADVP then)
   (VP responds
       (PP by
	   (NP an (VP increased) output
	       (PP of
		   (NP TSH)))))
   ,
   (S (NP *)
      (VP causing
	  (NP the thyroid)
	  (S (NP *)
	     (AUX to)
	     (VP enlarge)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S (NP The effect
        (PP of
            (NP (NP drugs)
		(SBAR (WHNP that)
		      (S  (NP T) 
			  (VP act
			      (PP on
				  (NP the (ADJP iodide-concentrating)
				      mechanism))))))))
    (AUX can)
    (VP be
	(VP counteracted
	     
	    (PP by
		(NP addition
		    (PP of
			(NP  (ADJP relatively
				   large) amounts
				   (PP of
				       (NP iodine))))
		    (PP to
			(NP the diet)))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP The antithyroid drugs
      (PP of
	  (NP the thiouracil type)))
  ,
  (ADVP however)
  ,
  (AUX are)
  (NEG not)
  (VP antagonised
	 
      (PP by
	  (NP such means))))
 .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP Besides
       (NP those
	   (PP of
	       (NP the (ADJP thiouracil and resorcinol) types))))
   ,
   (S (NP
       certain antithyroid
       drugs)
      (AUX have)
      (VP been
	  (VP found
		 
	      (PP in
		  (NP (VP  naturally
			   occurring)
		      foods))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (NP The
	   (VP (ADVP  most conclusively)
	       identified))
       (VP is
	   (NP (NP L-5-vinyl-2-thio-oxazolidone)
	       ,
	       (SBAR 
		(WHNP which)
		(S (NP T)
		   (AUX was)
		   (VP isolated
		       (PP from
			   (NP rutabaga))))))))
    *LRB*
    (NP (NP Greer)
	,
	(NP 1950))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP It)
   (AUX is)
   (VP presumed
	     
       (S (NP *)
	  (AUX to)
	  (VP occur
	      (PP in
		  (NP other members
		      (PP of
			  (NP the Brassica family))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (NP There)
       (VP is
	   (NP some evidence
	       (SBAR that
		     (S (NP   (VP naturally
				  occurring)
			      goitrogens)
			(AUX may)
			(VP play
			    (NP a role)
			    (PP in
				(NP the development
				    (PP of
					(NP goitre)))))
			,
			(PP  (ADVP particularly)
			     in
			     (NP (NP Tasmania)
				 and
				 (NP Australia))))))))
    *LRB*
    (NP (NP (NP Clements)
	    and
	    (NP Wishart))
	,
	(NP 1956))
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP There)
      (S (NP it)
	 (VP seems
	     (SBAR that
		   (S (NP (NP the goitrogen)
			  (VP ingested
			      (PP by
				  (NP dairy animals))))
		      (X (VP is
			     (NP itself)
			     (ADJP inactive))
			 but
			 (X  
			  (AUX is)
			  (VP converted
	    
			      (PP in
				  (NP the animal))
			      (PP to
				  (NP (NP an active goitrogen)
				      ,
				      (SBAR 
				       (WHNP which)
				       (S (NP T)
					  (AUX is)
					  (ADVP then)
					  (VP secreted
	      
					      (PP in
						  (NP the milk)))))))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  (NP (NP F .)
       (NP Dietary influences)))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (PP Besides
      (NP the presence
	  (PP of
	      (NP goitrogens))
	  (PP in
	      (NP the diet))))
  ,
  (S (NP the level
	 (PP of
	     (NP (NP iodine)
		 (NP itself)))
	 (PP in
	     (NP the diet)))
     (VP plays
	 (NP a major role)
	 (PP in
	     (S (NP *) 
		(VP governing
		    (NP the activity
			(PP of
			    (NP the thyroid gland)))))))))
 .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S  
      (PP (PP In
	      (NP the experimental animal))
	  and
	  (PP in
	      (NP man)))
      (S (NP gross deficiency
	     (PP in
		 (NP dietary iodine)))
	 (VP causes
	     (NP (NP thyroid hyperplasia)
		 ,
		 (NP hypertrophy)
		 and
		 (NP (VP increased)
		     thyroid activity)))))
     *LRB*
     (NP (NP (NP (NP Money)
		 ,
		 (NP Rall)
		 and
		 (NP Rawson))
	     ,
	     (NP 1952))
	 ;
	 ;
	 (NP (NP (NP Stanbury)
		 ,
		 (NP Brownell)
		 ,
		 (NP Riggs)
		 ,
		 (NP Perinetti)
		 ,
		 (NP Itoiz)
		 ,
		 and
		 (NP Del Castillo))
	     ,
	     (NP 1954)))
     *RRB*)
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (PP In
	 (NP man))
     (S  
      (NP (NP the normal level
	      (PP of
		  (NP iodine))
	      (PP in
		  (NP the diet)))
	  and
	  (NP (NP the level)
	      (ADJP necessary
		    (S (NP *)
		       (AUX to)
		       (VP prevent
			   (NP development
			       (PP of
				   (NP goitre))))))))
      (VP is
	  (NP (ADVP about)
	      100 ** ymg
	      (PP per
		  (NP day))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP With
       (NP 
	lower
	levels))
   ,
   (S (NP (NP thyroid hypertrophy)
	  and
	  (NP (VP increased)
	      thyroid blood-flow))
      (VP enable
	  (NP the thyroid)
	  (S (NP *)
	     (AUX to)
	     (VP accumulate
		 (NP a
		     larger
		     proportion
		     (PP of
			 (NP the daily intake
			     (PP of
				 (NP iodine))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Further)
      ,
      (S (NP the gland)
	 (VP is
	     (ADJP able
		   (S (NP *)
		      (AUX to)
		      (VP re-use
			  (NP a
			      larger
			      fraction
			      (PP of
				  (NP (NP the thyroid hormone)
				      (VP de-iodinated
					  (ADVP peripherally)))))))))))
  .) 
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP the presence
	   (PP of
	       (NP a low iodine intake))))
   ,
   (S (NP (NP thyroglobulin)
	  (VP labelled
	      (PP in
		  (NP vivo))
	      (PP with
		  (NP A[fj]))))
      (AUX is)
      (VP found
	       
	  (S (NP *)
	     (AUX to)
	     (VP contain
		 (NP   more
		       mono-iodotyrosine
		       (PP than
			   (ADJP normal))))))
      ,
      (S (NP the amounts
	     (PP of
		 (NP  (NP di-iodotyrosine) and (NP iodothyronines))))
	 (AUX being)
	 (VP  (ADVP correspondingly)
	      reduced))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP This)
   (VP appears
       (S (NP *)
	  (AUX to)
	  (VP result
	      (PP from
		  (NP both
		      (NP a  (ADJP reduced) amount
			  (PP of
			      (NP the iodine substrate)))
		      and
		      (NP a
			  (ADJP  more
				 rapid) secretion
			  (PP of
			      (NP (VP  newly
				       iodinated)
				  thyroglobulin)))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (SBAR  If
	  (S (NP the deficiency)
	     (VP persists
		 (ADVP long
		       enough))))
   ,
   (S (NP it
	  (S-7 *pseudo-attach*))
      (VP is
	  (ADJP reasonable))
      (S-7 (NP *)
	   (AUX to)
	   (VP suppose
	       (SBAR that
		     (S (NP the A[fj] label)
			(AUX will)
			(VP reflect
			    (NP the A[fj] distribution
				(PP in
				    (NP the thyroglobulin))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Similar results)
   (AUX might)
   (VP be
       (VP expected
		 
	   (PP from
	       (NP the influence
		   (PP of
		       (NP (NP drugs
			       or
			       pathological conditions)
			   (SBAR (WHNP that)
				 (S   (NP T) 
				      (VP (VP limit
					      (NP (NP iodide trapping)
						  ,
						  or
						  (NP organification)))
					  ,
					  or
					  (VP accelerate
					      (NP thyroglobulin proteolysis))))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  (NP (NP B .)
       (NP The (ADJP thyroid-stimulating) hormone)))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (NP The name)
      (NP (NP (ADJP thyroid-stimulating) hormone)
	  *LRB*
	  (NP TSH)
	  *RRB*))
  (AUX has)
  (VP been
      (VP given
	     
	  (PP to
	      (NP (NP a substance)
		  (VP found
		      (PP in
			  (NP the
			      anterior pituitary
			      gland
			      (PP of
				  (NP (NP all species
					  (PP of
					      (NP animal)))
				      (VP  (ADVP so)
					   tested
					   (PP for
					       (NP its presence)))))))))))))
 .)
(  END_OF_TEXT_UNIT)
( (S
   (NP The hormone)
   (AUX has)
   (ADVP also)
   (VP been
       (VP called
	   (NP (NP thyrotrophin)
	       or
	       (NP thyrotrophic hormone)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S (PP At
	    (NP the present time))
	(S
	 (NP we)
	 (AUX do)
	 (NEG not)
	 (VP know
	     (SBAR (WHPP by
			 (WHNP what
			       biochemical mechanism))
		   (S (NP TSH)
		      (VP acts
	        
			  (PP on
			      (NP the thyroid))))))))
     ,
     but
     (S (PP for
	    (NP bio-assay
		(PP of
		    (NP the hormone))))
	(S
	 (NP there)
	 (VP are
	     (NP (NP (NP a number
			 (PP of
			     (NP properties)))
		     (SBAR (WHPP by
				 (WHNP which))
			   (S (NP its activity)
			      (AUX may)
			      (VP be
				  (VP estimated
				      )))))
		 ,
		 (VP including
		     (NP (NP release
			     (PP of
				 (NP iodine))
			     (PP from
				 (NP the thyroid)))
			 ,
			 (NP increase
			     (PP in
				 (NP thyroid weight)))
			 ,
			 (NP  increase
			      (PP in
				  (NP mean height
				      (PP of
					  (NP the follicular cells)))))
			 and
			 (NP increase
			     (PP in
				 (NP the thyroidal uptake
				     (PP of
					 (NP A[fj]))))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Here)
      (S (NP we)
	 (AUX shall)
	 (VP restrict
	     (NP discussion)
	     (PP to
		 (NP (NP those methods)
		     (SBAR (WHNP that)
			   (S  (NP T) 
			       (VP appear
				   (ADJP  sufficiently
					  sensitive and precise
					  (PP for
					      (S (NP *) 
						 (VP determining
						     (NP the concentration
							 (PP of
							     (NP TSH))
							 (PP in
							     (NP blood)))))))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S (S  (NP (NP Brown)
	    *LRB*
	    (NP 1959)
	    *RRB*)
	(AUX has)
	(VP reviewed
	    (ADVP generally)
	    (NP the various methods
		(PP of
		    (S (NP *) 
		       (VP assaying
			   (NP TSH)))))))
    ,
    and
    (S (NP the reader)
       (AUX is)
       (VP referred
	    
	   (PP to
	       (NP her paper)))
       (PP for
	   (NP 
	    further
	    information
	    (PP on
		(NP the subject))))))
 .)
(  END_OF_TEXT_UNIT)
(  (NP (NP 1
	   .)
       (NP Chemical constitution
	   and
	   physical properties
	   (PP of
	       (NP pituitary tsh)))))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(
 (S  (ADVP (ADVP As
		 long)
	   ago
	   (PP as
	       (NP 1851)))
     (S (NP it)
	(AUX was)
	(VP pointed
	  
	    (PRT out)
	    (PP by
		(NP (NP Niepce)
		    *LRB*
		    (NP 1851)
		    *RRB*))
	    (SBAR that
		  (S (NP there)
		     (VP is
			 (NP a connection
			     (PP between
				 (NP (NP the pituitary)
				     and
				     (NP the thyroid))))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (NP This connection)
    (AUX was)
    (VP clarified
		 
	(PP by
	    (NP (NP (NP (NP Smith)
			and
			(NP Smith))
		    *LRB*
		    (NP 1922)
		    *RRB*)
		,
		(SBAR  
		 (WHNP who)
		 (S (NP T)
		    (VP showed
			(SBAR that
			      (S (NP saline extracts
				     (PP of
					 (NP 
					  fresh bovine
					  pituitary glands)))
				 (AUX could)
				 (VP re-activate
				     (NP the (VP atrophied) thyroids
					 (PP of
					     (NP (VP hypophysectomised)
						 tadpoles)))))))))))))
 .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP The first attempts
      (S (NP *)
	 (AUX to)
	 (VP isolate
	     (NP TSH))))
  (VP came
      (ADVP (ADVP (NP a decade)
		  later)
	    ,
	    (SBAR 
	     (WHADVP when)
	     (S (NP (NP (NP Janssen)
			and
			(NP Loeser))
		    *LRB*
		    (NP 1931)
		    *RRB*)
		(VP used
		    (NP trichloroacetic acid)
		    (S (NP *)
		       (AUX to)
		       (VP separate
			   (NP the
			       soluble
			       TSH)
			   (PP from
			       (NP insoluble impurities))))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( 
 (S (PP After
	(NP their work))
    (S (NP other investigators)
       (VP applied
	   (NP (NP salt-fractionation techniques)
	       (ADVP-8 *pseudo-attach*))
	   (PP to
	       (NP the problem))
	   ,
	   (ADVP-8 as
		   well
		   (PP as
		       (NP fractionation
			   (PP with
			       (NP (NP organic solvents)
				   ,
				   (ADJP such
					 (PP as
					     (NP acetone)))))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  (NP (NP Albert)
	 *LRB*
	 (NP 1949)
	 *RRB*)
     (AUX has)
     (VP concluded
	 (SBAR that
	       (S (NP (NP the
			  (ADJP  most active)
			  preparations
			  (PP of
			      (NP TSH)))
		      (VP made
			  (PP during
			      (NP (NP this period)
				  ,
				  (PP (PP from
					  (NP 1931))
				      (PP to
					  (NP 1945)))
				  ,))))
		  (VP were
		      (ADVP probably)  
		      (ADJP (NP (ADVP about)
				100
				(PP to
				    (NP 300 times)))
			    as
			    potent
			    (PP as
				(NP the starting material))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( 
 (S  (NP Much
	 (PP of
	     (NP this work)))
     (AUX has)
     (VP been
	 (VP reviewed
	      
	     (PP (PP by
		     (NP (NP White)
			 *LRB*
			 (NP 1944)
			 *RRB*))
		 and
		 (PP by
		     (NP (NP Albert)
			 *LRB*
			 (NP 1949)
			 *RRB*))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (NP Developments
	(PP up
	    (PP to
		(NP (ADVP about)
		    1957))))
    (AUX have)
    (VP been
	(VP discussed
	     
	    (PP by
		(NP (NP Sonenberg)
		    *LRB*
		    (NP 1958)
		    *RRB*)))))
 .)
(  END_OF_TEXT_UNIT)
( (S (S  
      (PP In
	  (NP the
	      last
	      few years))
      ,
      (S (NP the application
	     (PP of
		 (NP 
		  chromatographic and other modern
		  techniques))
	     (PP to
		 (NP the problem
		     (PP of
			 (S  (NP *) 
			     (VP isolating
				 (NP TSH)))))))
	 (AUX has)
	 (VP led
	     (PP to
		 (NP 
		  further
		  purification)))))
     *LRB*
     (NP (NP (NP (NP Bates)
		 and
		 (NP Condliffe))
	     ,
	     (NP 1960))
	 ;
	 ;
	 (NP (NP (NP Pierce)
		 ,
		 (NP Carsten)
		 and
		 (NP Wynston))
	     ,
	     (NP 1960)))
     *RRB*)
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP (NP The
	   (ADJP most active)
	   preparations)
       (VP obtained
	   (PP by
	       (NP these two groups
		   (PP of
		       (NP investigators))))))
   (VP appear
       (S (NP *)
	  (AUX to)
	  (VP be
	      (ADJP similar
		    (PP in
			(NP (NP potency)
			    ,
			    (NP composition)
			    and
			    (NP physical properties))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S
   (NP Two problems)
   (VP present
       (NP themselves))
   (PP in
       (S (NP *) 
	  (VP considering
	      (NP any hormone
		  (PP in
		      (NP blood)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((SQ   
  (ADVP First)
  ,
  (SQ  
   (VP is)
   (NP the circulating form
       (PP of
	   (NP the hormone)))
   (NP the
       same
       (PP as
	   (NP (NP that)
	       (VP found
		   (PP in
		       (NP (NP the gland)
			   (SBAR 
			    (WHADVP where)
			    (S (NP it)
			       (AUX is)
			       (VP (VP synthesised)
				   and
				   (VP stored))))))))))))
 ?
 ?) 
(  END_OF_TEXT_UNIT)
( (SBARQ  
   (ADVP Second)
   ,
   (SBARQ (SBARQ  
	   (WHNP what)
	   (SQ  
	    (VP is)
	    (NP its concentration)
	    (PP in
		(NP normal circumstances))
	    (NP T)))
	  and
	  (SBARQ (SBARQ (WHPP in
			      (WHNP what circumstances))
			(SQ  
			 (AUX will)
			 (NP this concentration)
			 (VP depart
			     (PP from
				 (NP the normal level)))))
		 and
		 (X (WHPP in
			  (WHNP which direction))))))
  ?
  ?)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP It
       (S-9 *pseudo-attach*))
   (VP is
       (ADVP therefore)
       (ADJP necessary))
   (S-9 (NP *)
	(AUX to)
	(VP consider
	    (NP the properties
		(PP of
		    (NP pituitary
			TSH)))))
   (SBAR if
	 (S (NP the fragmentary chemical information
		(PP about
		    (NP blood
			TSH)))
	    (VP is
		(S (NP *)
		   (AUX to)
		   (VP be
		       (VP discussed
			   (ADVP rationally))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S (NP The importance
        (PP of
	    (S (NP *) 
	       (VP knowing
		   (SBAR 
		    (WHPP in
			  (WHNP what chemical forms))
		    (S (NP the hormone)
		       (AUX may)
		       (VP exist)))))))
    (AUX is)
    (VP accentuated
	     
	(PP by
	    (NP (NP the recent observation
		    (SBAR that
			  (S  (NP there)
			      (VP exists
				  (NP an
				      (ADJP  abnormally
					     long-acting)
				      TSH)
				  (PP in
				      (NP (NP blood)
					  (VP drawn
					      (PP from
						  (NP many thyrotoxic patients)))))))))
		*LRB*
		(NP (NP Adams)
		    ,
		    (NP 1958))
		*RRB*))))
 .) 
(  END_OF_TEXT_UNIT)
( 
 (S  
  (NP (SBAR  Whether
	     (S (NP this
		    abnormal
		    TSH)
		(VP (VP differs
			(ADVP chemically)
			(PP from
			    (NP pituitary
				TSH)))
		    ,
		    or
		    (VP is
			,
			(ADVP alternatively)
			,
			(NP normal
			    TSH
			    (PP with
				(NP (NP its period
					(PP of
					    (NP effectiveness)))
				    (VP modified
					(PP by
					    (NP some other blood constituent)))))))
		    ,))))
  (AUX can)
  (NEG not)
  (VP be
      (VP decided))
  (PP without
      (NP (NP chemical study
	      (PP of
		  (NP the activity
		      (PP in
			  (NP the blood
			      (PP of
				  (NP these patients)))))))
	  and
	  (NP a comparison
	      (PP of
		  (NP (NP the substance)
		      (ADJP responsible
			    (PP for
				(NP the blood activity)))))
	      (PP with
		  (NP pituitary A[fj]))))))
 .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (S (NP *) 
	  (VP evaluating
	      (NP data
		  (PP on
		      (NP the concentration
			  (PP of
			      (NP TSH))
			  (PP in
			      (NP blood))))))))
   ,
   (S (NP one)
      (AUX must)
      (VP examine
	  (ADVP critically)
	  (NP (NP the bio-assay methods)
	      (VP used
		  (S (NP *)
		     (AUX to)
		     (VP obtain
			 (NP them))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( 
 (S (NP (NP The introduction
	    (PP of
		(NP the United States Pharmacopoeia reference standard))
	    (PP in
		(NP 1952)))
	and
	(NP the redefinition
	    and
	    equating
	    (PP of
		(NP the USP
		    and
		    international units
		    (PP of
			(NP (ADJP thyroid-stimulating) activity))))))
    (AUX have)
    (VP made
	(NP it
	    (S-10 *pseudo-attach*))
	(ADJP possible)
	(S-10 (NP *)
	      (AUX to)
	      (VP compare
		  (NP (NP results)
		      (VP published
			  (PP by
			      (NP different investigators))
			  (PP  since
			       (NP that time))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP We)
   (AUX should)
   (VP like
       (S (NP *)
	  (AUX to)
	  (VP re-emphasise
	      (NP the importance
		  (PP (PP of
			  (S  (NP *) 
			      (VP stating
				  (NP results)
				  (PP (ADVP solely)
				      in
				      (NP terms
					  (PP of
					      (NP international units
						  (PP of
						      (NP TSH
							  activity)))))))))
		      and
		      (PP of
			  (S (NP *)  
			     (VP avoiding
				 (NP the re-introduction
				     (PP of
					 (NP biological units))))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP For
       (NP the
	   most
	   part))
   ,
   (S (NP this discussion)
      (AUX will)
      (VP be
	  (VP confined
		  
	      (PP to
		  (NP (NP results)
		      (VP obtained
			  (PP  since
			       (NP the introduction
				   (PP of
				       (NP the reference standard)))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (NP (NP A .)
      (NP Standard preparations and units
	  (PP of
	      (NP (ADJP thyroid-stimulating) activity)))))
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (NP (NP The international unit)
	  *LRB*
	  (NP u.)
	  *RRB*
	  ,)
      (VP adopted
	  (S (NP *)
	     (AUX to)
	     (VP make
		 (ADJP possible)
		 (NP the comparison
		     (PP of
			 (NP results
			     (PP from
				 (NP different laboratories))))))))
      *LRB*
      (NP (NP (NP Mussett)
	      and
	      (NP Perry))
	  ,
	  (NP 1955))
      *RRB*
      ,)
  (AUX has)
  (VP been
      (VP defined
	     
	  (PP as
	      (NP (NP the amount
		      (PP of
			  (NP activity)))
		  (ADJP present
			(PP in
			    (NP 13.5 mg
				(PP of
				    (NP the International Standard Preparation))))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The international unit)
   (VP is
       (ADJP equipotent
	     (PP with
		 (NP (NP (NP the USP unit)
			 (VP adopted
			     (PP in
				 (NP 1952))))
		     ,
		     (SBAR 
		      (WHNP which)
		      (S (NP T)
			 (AUX was)
			 (VP defined
		     
			     (PP as
				 (NP (NP the amount
					 (PP of
					     (NP  activity)))
				     (ADJP present
					   (PP in
					       (NP 20 mg
						   (PP of
						       (NP the USP reference substance)))))))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
